Is there progress? An overview of selecting biomarker candidates for major depressive disorder

Frontiers in Psychiatry

Volumn 7, Issue APR, 2016, Pages

  Young, Juan Joseph ^a,b,c   Silber, Tim ^a   Bruno, Davide ^d   Galatzer Levy, Isaac Robert ^e   Pomara, Nunzio ^a,e,f   Marmar, Charles Raymond ^e,f  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c METROHEALTH MEDICAL CENTER   (United States)

^d LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NEW YORK UNIVERSITY   (United States)

Author keywords

Assay; Biomarker; Diagnosis; Major depression; Multiplex; State; Trait

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; CORTICOTROPIN RELEASING FACTOR; ESCITALOPRAM; GLUTATHIONE; HYDROCORTISONE; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6; ISOPROSTANE DERIVATIVE; LIOTHYRONINE; MICRORNA; NEUROTROPHIN; NORTRIPTYLINE; OREXIN; THYROID ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROXINE; TUMOR NECROSIS FACTOR ALPHA;

CORTISOL AWAKENING RESPONSE; DEPRESSION; DEXAMETHASONE SUPPRESSION TEST; DIAGNOSTIC VALUE; DNA METHYLATION; HISTONE MODIFICATION; HORMONE RESPONSE; HUMAN; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; MAJOR DEPRESSION; MELANCHOLIA; METABOLOMICS; NONHUMAN; OXIDATIVE STRESS; PROTEOMICS; QUALITY OF LIFE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID DISEASE; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE;

EID: 84975291035     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2016.00072     Document Type: Review

References (225)

1. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA (2003) 289(23):3095-105. doi: 10.1001/jama.289.23.3095
2. Kessler RC. The costs of depression. Psychiatr Clin North Am (2012) 35(1):1-14. doi:10.1016/j.psc.2011.11.005
3. World Health Organization. Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. Geneva: World Health Organization (2009). 68 p. Order Number 11500772.
4. Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med (2013) 43(3):471-81. doi:10.1017/S0033291712001511
5. Uher R, Payne JL, Pavlova B, Perlis RH. Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV. Depress Anxiety (2014) 31(6):459-71. doi:10.1002/da.22217
6. Lichtblau N, Schmidt FM, Schumann R, Kirkby KC, Himmerich H. Cytokines as biomarkers in depressive disorder: current standing and prospects. Int Rev Psychiatry (2013) 25(5):592-603. doi:10.3109/09540261.2013.813442
7. Lopresti AL, Maker GL, Hood SD, Drummond PD. A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog Neuropsychopharmacol Biol Psychiatry (2014) 48:102-11. doi:10.1016/j.pnpbp.2013.09.017
8. Mamdani F, Martin MV, Lencz T, Rollins B, Robinson DG, Moon EA, et al. Coding and noncoding gene expression biomarkers in mood disorders and schizophrenia. Dis Markers (2013) 35(1):11-21. doi:10.1155/2013/748095
9. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry (2009) 65(9):732-41. doi:10.1016/j.biopsych.2008.11.029
10. Uddin M. Blood-based biomarkers in depression: emerging themes in clinical research. Mol Diagn Ther (2014) 18(5):469-82. doi:10.1007/s40291-014-0108-1
11. Boksa P. A way forward for research on biomarkers for psychiatric disorders. J Psychiatry Neurosci (2013) 38(2):75-7. doi:10.1503/jpn.130018
12. Kunugi H, Hori H, Ogawa S. Biochemical markers subtyping major depressive disorder. Psychiatry Clin Neurosci (2015) 69(10):597-608. doi:10.1111/pcn.12299
13. Enaw JO, Smith AK. Biomarker development for brain-based disorders: recent progress in psychiatry. J Neurol Psychol (2013) 1(2):7. doi:10.13188/2332-3469.1000006
14. Woods AG, Iosifescu DV, Darie CC. Biomarkers in major depressive disorder: the role of mass spectrometry. Adv Exp Med Biol (2014) 806:545-60. doi:10.1007/978-3-319-06068-2_27
15. Lener MS, Iosifescu DV. In pursuit of neuroimaging biomarkers to guide treatment selection in major depressive disorder: a review of the literature. Ann N Y Acad Sci (2015) 1344:50-65. doi:10.1111/nyas.12759
16. Sundermann B, Olde Lütke Beverborg M, Pfleiderer B. Toward literature-based feature selection for diagnostic classification: a meta-analysis of resting-state fMRI in depression. Front Hum Neurosci (2014) 8:692. doi:10.3389/fnhum.2014.00692
17. Wolfers T, Buitelaar JK, Beckmann CF, Franke B, Marquand AF. From estimating activation locality to predicting disorder: a review of pattern recognition for neuroimaging-based psychiatric diagnostics. Neurosci Biobehav Rev (2015) 57:328-49. doi:10.1016/j.neubiorev.2015.08.001
18. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology (2000) 23(5):477-501. doi:10.1016/S0893-133X(00)00159-7
19. Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry (2000) 57(10):925-35. doi:10.1001/archpsyc.57.10.925
20. Lavebratt C, Aberg E, Sjöholm LK, Forsell Y. Variations in FKBP5 and BDNF genes are suggestively associated with depression in a Swedish population-based cohort. J Affect Disord (2010) 125(1-3):249-55. doi:10.1016/j.jad.2010.02.113
21. Lekman M, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, et al. The FKBP5-gene in depression and treatment response-an association study in the sequenced treatment alternatives to relieve depression (STAR*D) cohort. Biol Psychiatry (2008) 63(12):1103-10. doi:10.1016/j.biopsych.2007.10.026
22. Menke A, Klengel T, Rubel J, Brückl T, Pfister H, Lucae S, et al. Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression. Genes Brain Behav (2013) 12(3):289-96. doi:10.1111/gbb.12026
23. Zobel A, Schuhmacher A, Jessen F, Höfels S, von Widdern O, Metten M, et al. DNA sequence variants of the FKBP5 gene are associated with unipolar depression. Int J Neuropsychopharmacol (2010) 13(5):649-60. doi:10.1017/S1461145709991155
24. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci (2008) 31(9):464-8. doi:10.1016/j.tins.2008.06.006
25. Varghese FP, Brown ES. The hypothalamic-pituitary-adrenal axis in major depressive disorder: a brief primer for primary care physicians. Prim Care Companion J Clin Psychiatry (2001) 3(4):151-5. doi:10.4088/PCC.v03n0401
26. Shea A, Walsh C, Macmillan H, Steiner M. Child maltreatment and HPA axis dysregulation: relationship to major depressive disorder and post traumatic stress disorder in females. Psychoneuroendocrinology (2005) 30(2):162-78. doi:10.1016/j.psyneuen.2004.07.001
27. Aihara M, Ida I, Yuuki N, Oshima A, Kumano H, Takahashi K, et al. HPA axis dysfunction in unmedicated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal cortex and limbic/paralimbic regions. Psychiatry Res (2007) 155(3):245-56. doi:10.1016/j.pscychresns.2006.11.002
28. Kunugi H, Ida I, Owashi T, Kimura M, Inoue Y, Nakagawa S, et al. Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: a multicenter study. Neuropsychopharmacology (2006) 31(1):212-20. doi:10.1038/sj.npp.1300868
29. Vreeburg SA, Hoogendijk WJ, van Pelt J, Derijk RH, Verhagen JC, van Dyck R, et al. Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. Arch Gen Psychiatry (2009) 66(6):617-26. doi:10.1001/archgenpsychiatry.2009.50
30. Waters RP, Rivalan M, Bangasser DA, Deussing JM, Ising M, Wood SK, et al. Evidence for the role of corticotropin-releasing factor in major depressive disorder. Neurosci Biobehav Rev (2015) 58:63-78. doi:10.1016/j.neubiorev.2015.07.011
31. Heuser I, Yassouridis A, Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res (1994) 28(4):341-56. doi:10.1016/0022-3956(94)90017-5
32. Paslakis G, Krumm B, Gilles M, Schweiger U, Heuser I, Richter I, et al. Discrimination between patients with melancholic depression and healthy controls: comparison between 24-h cortisol profiles, the DST and the Dex/CRH test. Psychoneuroendocrinology (2011) 36(5):691-8. doi:10.1016/j.psyneuen.2010.10.002
33. Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom Med (2011) 73(2):114-26. doi:10.1097/PSY.0b013e31820ad12b
34. Owens M, Herbert J, Jones PB, Sahakian BJ, Wilkinson PO, Dunn VJ, et al. Elevated morning cortisol is a stratified population-level biomarker for major depression in boys only with high depressive symptoms. Proc Natl Acad Sci U S A (2014) 111(9):3638-43. doi:10.1073/pnas.1318786111
35. Nelemans SA, Hale WW III, Branje SJ, van Lier PA, Jansen LM, Platje E, et al. Persistent heightened cortisol awakening response and adolescent internalizing symptoms: a 3-year longitudinal community study. J Abnorm Child Psychol (2014) 42(5):767-77. doi:10.1007/s10802-013-9820-2
36. Mannie ZN, Harmer CJ, Cowen PJ. Increased waking salivary cortisol levels in young people at familial risk of depression. Am J Psychiatry (2007) 164(4):617-21. doi:10.1176/ajp.2007.164.4.617
37. Shibuya I, Nagamitsu S, Okamura H, Ozono S, Chiba H, Ohya T, et al. High correlation between salivary cortisol awakening response and the psychometric profiles of healthy children. Biopsychosoc Med (2014) 8(1):9. doi:10.1186/1751-0759-8-9
38. Allard JS, Tizabi Y, Shaffery JP, Trouth CO, Manaye K. Stereological analysis of the hypothalamic hypocretin/orexin neurons in an animal model of depression. Neuropeptides (2004) 38(5):311-5. doi:10.1016/j.npep.2004.06.004
39. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature (2008) 455(7215):894-902. doi:10.1038/nature07455
40. Brundin L, Björkqvist M, Petersén A, Träskman-Bendz L. Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur Neuropsychopharmacol (2007) 17(9):573-9. doi:10.1016/j.euroneuro.2007.01.005
41. Salomon RM, Ripley B, Kennedy JS, Johnson B, Schmidt D, Zeitzer JM, et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol Psychiatry (2003) 54(2):96-104. doi:10.1016/S0006-3223(02)01740-7
42. Berlin I, Payan C, Corruble E, Puech AJ. Serum thyroid-stimulating-hormone concentration as an index of severity of major depression. Int J Neuropsychopharmacol (1999) 2(2):105-10. doi:10.1017/S146114579900139X
43. Brouwer JP, Appelhof BC, Hoogendijk WJ, Huyser J, Endert E, Zuketto C, et al. Thyroid and adrenal axis in major depression: a controlled study in outpatients. Eur J Endocrinol (2005) 152(2):185-91. doi:10.1530/eje.1.01828
44. Chueire VB, Romaldini JH, Ward LS. Subclinical hypothyroidism increases the risk for depression in the elderly. Arch Gerontol Geriatr (2007) 44(1):21-8. doi:10.1016/j.archger.2006.02.001
45. Demet MM, Ozmen B, Deveci A, Boyvada S, Adigüzel H, Aydemir O. Depression and anxiety in hyperthyroidism. Arch Med Res (2002) 33(6):552-6. doi:10.1016/S0188-4409(02)00410-1
46. Demet MM, Ozmen B, Deveci A, Boyvada S, Adiguzel H, Aydemir O. Depression and anxiety in hypothyroidism. West Indian Med J (2003) 52(3):223-7.
47. Gold MS, Pottash AL, Extein I. "Symptomless" autoimmune thyroiditis in depression. Psychiatry Res (1982) 6(3):261-9. doi:10.1016/0165-1781(82)90015-4
48. Haggerty JJ Jr, Garbutt JC, Evans DL, Golden RN, Pedersen C, Simon JS, et al. Subclinical hypothyroidism: a review of neuropsychiatric aspects. Int J Psychiatry Med (1990) 20(2):193-208. doi:10.2190/ADLY-1UU0-1A8L-HPXY
49. Holtmann M, Duketis E, Goth K, Poustka L, Boelte S. Severe affective and behavioral dysregulation in youth is associated with increased serum TSH. J Affect Disord (2010) 121(1-2):184-8. doi:10.1016/j.jad.2009.06.009
50. Nemeroff CB, Simon JS, Haggerty JJ Jr, Evans DL. Antithyroid antibodies in depressed patients. Am J Psychiatry (1985) 142(7):840-3. doi:10.1176/ajp.142.7.840
51. Blum MR, Wijsman LW, Virgini VS, Bauer DC, den Elzen WP, Jukema JW, et al. Subclinical thyroid dysfunction and depressive symptoms among elderly: a prospective cohort study. Neuroendocrinology (2015). doi:10.1159/000437387
52. Engum A, Bjøro T, Mykletun A, Dahl AA. Thyroid autoimmunity, depression and anxiety; are there any connections? An epidemiological study of a large population. J Psychosom Res (2005) 59(5):263-8. doi:10.1016/j.jpsychores.2005.04.002
53. Park YJ, Lee EJ, Lee YJ, Choi SH, Park JH, Lee SB, et al. Subclinical hypothyroidism (SCH) is not associated with metabolic derangement, cognitive impairment, depression or poor quality of life (QoL) in elderly subjects. Arch Gerontol Geriatr (2010) 50(3):e68-73. doi:10.1016/j.archger.2009.05.015
54. Kirkegaard C, Kørner A, Faber J. Increased production of thyroxine and inappropriately elevated serum thyrotropin in levels in endogenous depression. Biol Psychiatry (1990) 27(5):472-6. doi:10.1016/0006-3223(90)90438-8
55. Premachandra BN, Kabir MA, Williams IK. Low T3 syndrome in psychiatric depression. J Endocrinol Invest (2006) 29(6):568-72. doi:10.1007/BF03344150
56. Williams MD, Harris R, Dayan CM, Evans J, Gallacher J, Ben-Shlomo Y. Thyroid function and the natural history of depression: findings from the Caerphilly Prospective Study (CaPS) and a meta-analysis. Clin Endocrinol (Oxf) (2009) 70(3):484-92. doi:10.1111/j.1365-2265.2008.03352.x
57. Carta MG, Loviselli A, Hardoy MC, Massa S, Cadeddu M, Sardu C, et al. The link between thyroid autoimmunity (antithyroid peroxidase autoantibodies) with anxiety and mood disorders in the community: a field of interest for public health in the future. BMC Psychiatry (2004) 4:25. doi:10.1186/1471-244X-4-25
58. Fam J, Rush AJ, Burt T, Chan ES, Siddiqui FJ, Assam PN, et al. Thyroid autoimmune antibodies and major depressive disorder in women. Ann Acad Med Singapore (2015) 44(8):284-9.
59. Kuijpens JL, Vader HL, Drexhage HA, Wiersinga WM, van Son MJ, Pop VJ. Thyroid peroxidase antibodies during gestation are a marker for subsequent depression postpartum. Eur J Endocrinol (2001) 145(5):579-84. doi:10.1530/eje.0.1450579
60. Müssig K, Künle A, Säuberlich AL, Weinert C, Ethofer T, Saur R, et al. Thyroid peroxidase antibody positivity is associated with symptomatic distress in patients with Hashimoto's thyroiditis. Brain Behav Immun (2012) 26(4):559-63. doi:10.1016/j.bbi.2012.01.006
61. Haggerty JJ Jr, Silva SG, Marquardt M, Mason GA, Chang HY, Evans DL, et al. Prevalence of antithyroid antibodies in mood disorders. Depress Anxiety (1997) 5(2):91-6. doi:10.1002/(SICI)1520-6394(1997)5:2<91::AID-DA5>3.3.CO;2-K
62. Fjaellegaard K, Kvetny J, Allerup PN, Bech P, Ellervik C. Well-being and depression in individuals with subclinical hypothyroidism and thyroid autoimmunity-a general population study. Nord J Psychiatry (2015) 69(1):73-8. doi:10.3109/08039488.2014.929741
63. van de Ven AC, Muntjewerff JW, Netea-Maier RT, de Vegt F, Ross HA, Sweep FC, et al. Association between thyroid function, thyroid autoimmunity, and state and trait factors of depression. Acta Psychiatr Scand (2012) 126(5):377-84. doi:10.1111/j.1600-0447.2012.01870.x
64. Wei J, Sun G, Zhao L, Liu X, Lin D, Li T, et al. Hair thyroid hormones concentration in patients with depression changes with disease episodes in female Chinese. Psychiatry Res (2014) 220(1-2):251-3. doi:10.1016/j.psychres.2014.07.029
65. Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry (2009) 66(3):287-92. doi:10.1016/j.biopsych.2009.01.030
66. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry (1995) 19(1):11-38. doi:10.1016/0278-5846(94)00101-M
67. Maes M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett (2008) 29(3):287-91.
68. Raison CL, Borisov AS, Majer M, Drake DF, Pagnoni G, Woolwine BJ, et al. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry (2009) 65(4):296-303. doi:10.1016/j.biopsych.2008.08.010
69. Uddin M, Koenen KC, Aiello AE, Wildman DE, de los Santos R, Galea S. Epigenetic and inflammatory marker profiles associated with depression in a community-based epidemiologic sample. Psychol Med (2011) 41(5):997-1007. doi:10.1017/S0033291710001674
70. Stelzhammer V, Haenisch F, Chan MK, Cooper JD, Steiner J, Steeb H, et al. Proteomic changes in serum of first onset, antidepressant drug-naïve major depression patients. Int J Neuropsychopharmacol (2014) 17(10):1599-608. doi:10.1017/S1461145714000819
71. Hayley S, Poulter MO, Merali Z, Anisman H. The pathogenesis of clinical depression: stressor-and cytokine-induced alterations of neuroplasticity. Neuroscience (2005) 135(3):659-78. doi:10.1016/j.neuroscience.2005.03.051
72. Brydon L, Harrison NA, Walker C, Steptoe A, Critchley HD. Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol Psychiatry (2008) 63(11):1022-9. doi:10.1016/j.biopsych.2007.12.007
73. Capuron L, Pagnoni G, Demetrashvili MF, Lawson DH, Fornwalt FB, Woolwine B, et al. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology (2007) 32(11):2384-92. doi:10.1038/sj.npp.1301362
74. Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, Irwin MR. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry (2010) 68(8):748-54. doi:10.1016/j.biopsych.2010.06.010
75. Miller AH, Haroon E, Raison CL, Felger JC. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety (2013) 30(4):297-306. doi:10.1002/da.22084
76. Kalia M, Costa E Silva J. Biomarkers of psychiatric diseases: current status and future prospects. Metabolism (2015) 64(3 Suppl 1):S11-5. doi:10.1016/j.metabol.2014.10.026
77. Motivala SJ, Sarfatti A, Olmos L, Irwin MR. Inflammatory markers and sleep disturbance in major depression. Psychosom Med (2005) 67(2):187-94. doi:10.1097/01.psy.0000149259.72488.09
78. Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol (2001) 11(3):203-8. doi:10.1016/S0924-977X(01)00081-5
79. Brummett BH, Boyle SH, Ortel TL, Becker RC, Siegler IC, Williams RB. Associations of depressive symptoms, trait hostility, and gender with C-reactive protein and interleukin-6 response after emotion recall. Psychosom Med (2010) 72(4):333-9. doi:10.1097/PSY.0b013e3181d2f104
80. Miller GE, Cole SW. Clustering of depression and inflammation in adolescents previously exposed to childhood adversity. Biol Psychiatry (2012) 72(1):34-40. doi:10.1016/j.biopsych.2012.02.034
81. Slopen N, Kubzansky LD, McLaughlin KA, Koenen KC. Childhood adversity and inflammatory processes in youth: a prospective study. Psychoneuroendocrinology (2013) 38(2):188-200. doi:10.1016/j.psyneuen.2012.05.013
82. Vetter ML, Wadden TA, Vinnard C, Moore RH, Khan Z, Volger S, et al. Gender differences in the relationship between symptoms of depression and high-sensitivity CRP. Int J Obes (Lond) (2013) 37(Suppl 1):S38-43. doi:10.1038/ijo.2013.95
83. Valkanova V, Ebmeier KP, Allan CL. CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J Affect Disord (2013) 150(3):736-44. doi:10.1016/j.jad.2013.06.004
84. Rothermundt M, Arolt V, Peters M, Gutbrodt H, Fenker J, Kersting A, et al. Inflammatory markers in major depression and melancholia. J Affect Disord (2001) 63(1-3):93-102. doi:10.1016/S0165-0327(00)00157-9
85. Bremmer MA, Beekman AT, Deeg DJ, Penninx BW, Dik MG, Hack CE, et al. Inflammatory markers in late-life depression: results from a population-based study. J Affect Disord (2008) 106(3):249-55. doi:10.1016/j.jad.2007.07.002
86. Podlipnỳ J, Hess Z, Vrzalová J, Rosolová H, Beran J, Petrlová B. Lower serum levels of interleukin-6 in a population sample with symptoms of depression than in a population sample without symptoms of depression. Physiol Res (2010) 59(1):121-6.
87. Lamers F, Vogelzangs N, Merikangas KR, de Jonge P, Beekman AT, Penninx BW. Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol Psychiatry (2013) 18(6):692-9. doi:10.1038/mp.2012.144
88. Rudolf S, Greggersen W, Kahl KG, Hüppe M, Schweiger U. Elevated IL-6 levels in patients with atypical depression but not in patients with typical depression. Psychiatry Res (2014) 217(1-2):34-8. doi:10.1016/j.psychres.2014.02.016
89. Alvarez A, Faccioli J, Guinzbourg M, Castex MM, Bayón C, Masson W, et al. Endocrine and inflammatory profiles in type 2 diabetic patients with and without major depressive disorder. BMC Res Notes (2013) 6:61. doi:10.1186/1756-0500-6-61
90. Zeugmann S, Quante A, Heuser I, Schwarzer R, Anghelescu I. Inflammatory biomarkers in 70 depressed inpatients with and without the metabolic syndrome. J Clin Psychiatry (2010) 71(8):1007-16. doi:10.4088/JCP.08m04767blu
91. Au B, Smith KJ, Gariépy G, Schmitz N. C-reactive protein, depressive symptoms, and risk of diabetes: results from the English Longitudinal Study of Ageing (ELSA). J Psychosom Res (2014) 77(3):180-6. doi:10.1016/j.jpsychores.2014.07.012
92. Doyle TA, de Groot M, Harris T, Schwartz F, Strotmeyer ES, Johnson KC, et al. Diabetes, depressive symptoms, and inflammation in older adults: results from the health, aging, and body composition study. J Psychosom Res (2013) 75(5):419-24. doi:10.1016/j.jpsychores.2013.08.006
93. Viscogliosi G, Andreozzi P, Chiriac IM, Cipriani E, Servello A, Marigliano B, et al. Depressive symptoms in older people with metabolic syndrome: is there a relationship with inflammation? Int J Geriatr Psychiatry (2013) 28(3):242-7. doi:10.1002/gps.3817
94. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology (2000) 22(4):370-9. doi:10.1016/S0893-133X(99)00134-7
95. Munzer A, Sack U, Mergl R, Schönherr J, Petersein C, Bartsch S, et al. Impact of antidepressants on cytokine production of depressed patients in vitro. Toxins (Basel) (2013) 5(11):2227-40. doi:10.3390/toxins5112227
96. Myint AM, Leonard BE, Steinbusch HW, Kim YK. Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord (2005) 88(2):167-73. doi:10.1016/j.jad.2005.07.008
97. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) (2003) 170(4):429-33. doi:10.1007/s00213-003-1566-z
98. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology (2011) 36(12):2452-9. doi:10.1038/npp.2011.132
99. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry (2013) 70(1):31-41. doi:10.1001/2013.jamapsychiatry.4
100. Uher R, Tansey KE, Dew T, Maier W, Mors O, Hauser J, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry (2014) 171(12):1278-86. doi:10.1176/appi.ajp.2014.14010094
101. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci (2008) 9(1):46-56. doi:10.1038/nrn2297
102. Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev (2012) 36(2):764-85. doi:10.1016/j.neubiorev.2011.12.005
103. Müller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry (2007) 12(11):988-1000. doi:10.1038/sj.mp.4002006
104. Raison CL, Miller AH. Role of inflammation in depression: implications for phenomenology, pathophysiology and treatment. Mod Trends Pharmacopsychiatri (2013) 28:33-48. doi:10.1159/000343966
105. Young JJ, Bruno D, Pomara N. A review of the relationship between proinflammatory cytokines and major depressive disorder. J Affect Disord (2014) 169:15-20. doi:10.1016/j.jad.2014.07.032
106. Maes M, Galecki P, Chang YS, Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry (2011) 35(3):676-92. doi:10.1016/j.pnpbp.2010.05.004
107. Michel TM, Frangou S, Thiemeyer D, Camara S, Jecel J, Nara K, et al. Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder-a postmortem study. Psychiatry Res (2007) 151(1-2):145-50. doi:10.1016/j.psychres.2006.04.013
108. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol (2008) 11(6):851-76. doi:10.1017/S1461145707008401
109. Eren I, Naziroglu M, Demirdas A. Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain. Neurochem Res (2007) 32(7):1188-95. doi:10.1007/s11064-007-9289-x
110. Moretti M, Colla A, de Oliveira Balen G, dos Santos DB, Budni J, de Freitas AE, et al. Ascorbic acid treatment, similarly to fluoxetine, reverses depressive-like behavior and brain oxidative damage induced by chronic unpredictable stress. J Psychiatr Res (2012) 46(3):331-40. doi:10.1016/j.jpsychires.2011.11.009
111. Pal SN, Dandiya PC. Glutathione as a cerebral substrate in depressive behavior. Pharmacol Biochem Behav (1994) 48(4):845-51. doi:10.1016/0091-3057(94)90191-0
112. Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep (2003) 8(6):365-70. doi:10.1179/135100003225003393
113. Bilici M, Efe H, Köroglu MA, Uydu HA, Bekaroglu M, Deger O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord (2001) 64(1):43-51. doi:10.1016/S0165-0327(00)00199-3
114. Sarandol A, Sarandol E, Eker SS, Erdinc S, Vatansever E, Kirli S. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol (2007) 22(2):67-73. doi:10.1002/hup.829
115. Chung CP, Schmidt D, Stein CM, Morrow JD, Salomon RM. Increased oxidative stress in patients with depression and its relationship to treatment. Psychiatry Res (2013) 206(2-3):213-6. doi:10.1016/j.psychres.2012.10.018
116. Forlenza MJ, Miller GE. Increased serum levels of 8-hydroxy-2'-deoxyguanosine in clinical depression. Psychosom Med (2006) 68(1):1-7. doi:10.1097/01.psy.0000195780.37277.2a
117. Kodydková J, Vávrová L, Zeman M, Jirák R, Macásek J, Stanková B, et al. Antioxidative enzymes and increased oxidative stress in depressive women. Clin Biochem (2009) 42(13-14):1368-74. doi:10.1016/j.clinbiochem.2009.06.006
118. Szuster-Ciesielska A, Slotwinska M, Stachura A, Marmurowska-Michalowska H, Dubas-Slemp H, Bojarska-Junak A, et al. Accelerated apoptosis of blood leukocytes and oxidative stress in blood of patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry (2008) 32(3):686-94. doi:10.1016/j.pnpbp.2007.11.012
119. Lapidus KA, Gabbay V, Mao X, Johnson A, Murrough JW, Mathew SJ, et al. In vivo (1)H MRS study of potential associations between glutathione, oxidative stress and anhedonia in major depressive disorder. Neurosci Lett (2014) 569:74-9. doi:10.1016/j.neulet.2014.03.056
120. Irie M, Asami S, Ikeda M, Kasai H. Depressive state relates to female oxidative DNA damage via neutrophil activation. Biochem Biophys Res Commun (2003) 311(4):1014-8. doi:10.1016/j.bbrc.2003.10.105
121. Talarowska M, Bobinska K, Zajaczkowska M, Su KP, Maes M, Galecki P. Impact of oxidative/nitrosative stress and inflammation on cognitive functions in patients with recurrent depressive disorders. Med Sci Monit (2014) 20:110-5. doi:10.12659/MSM.889853
122. Smaga I, Niedzielska E, Gawlik M, Moniczewski A, Krzek J, Przegalinski E, et al. Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 2. Depression, anxiety, schizophrenia and autism. Pharmacol Rep (2015) 67(3):569-80. doi:10.1016/j.pharep.2014.12.015
123. Luca M, Luca A, Calandra C. Accelerated aging in major depression: the role of nitro-oxidative stress. Oxid Med Cell Longev (2013) 2013:230797. doi:10.1155/2013/230797
124. Rodrigues R, Petersen RB, Perry G. Parallels between major depressive disorder and Alzheimer's disease: role of oxidative stress and genetic vulnerability. Cell Mol Neurobiol (2014) 34(7):925-49. doi:10.1007/s10571-014-0074-5
125. Pomara N, Bruno D, Sarreal AS, Hernando RT, Nierenberg J, Petkova E, et al. Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. Am J Psychiatry (2012) 169(5):523-30. doi:10.1176/appi.ajp.2011.11081153
126. Joshi YB, Praticò D. Lipid peroxidation in psychiatric illness: overview of clinical evidence. Oxid Med Cell Longev (2014) 2014:828702. doi:10.1155/2014/828702
127. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci (2010) 64(4):341-57. doi:10.1111/j.1440-1819.2010.02113.x
128. Long Z, Duan X, Wang Y, Liu F, Zeng L, Zhao JP, et al. Disrupted structural connectivity network in treatment-naive depression. Prog Neuropsychopharmacol Biol Psychiatry (2015) 56:18-26. doi:10.1016/j.pnpbp.2014.07.007
129. Korgaonkar MS, Fornito A, Williams LM, Grieve SM. Abnormal structural networks characterize major depressive disorder: a connectome analysis. Biol Psychiatry (2014) 76(7):567-74. doi:10.1016/j.biopsych.2014.02.018
130. Boldrini M, Hen R, Underwood MD, Rosoklija GB, Dwork AJ, Mann JJ, et al. Hippocampal angiogenesis and progenitor cell proliferation are increased with antidepressant use in major depression. Biol Psychiatry (2012) 72(7):562-71. doi:10.1016/j.biopsych.2012.04.024
131. Masi G, Brovedani P. The hippocampus, neurotrophic factors and depression: possible implications for the pharmacotherapy of depression. CNS Drugs (2011) 25(11):913-31. doi:10.2165/11595900-000000000-00000
132. Diniz BS, Teixeira AL, Talib LL, Mendonça VA, Gattaz WF, Forlenza OV. Serum brain-derived neurotrophic factor level is reduced in antidepressant-free patients with late-life depression. World J Biol Psychiatry (2010) 11(3):550-5. doi:10.3109/15622970903544620
133. Lee BH, Kim YK. Reduced platelet BDNF level in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry (2009) 33(5):849-53. doi:10.1016/j.pnpbp.2009.04.002
134. Oral E, Canpolat S, Yildirim S, Gulec M, Aliyev E, Aydin N. Cognitive functions and serum levels of brain-derived neurotrophic factor in patients with major depressive disorder. Brain Res Bull (2012) 88(5):454-9. doi:10.1016/j.brainresbull.2012.03.005
135. Satomura E, Baba H, Nakano Y, Maeshima H, Suzuki T, Arai H. Correlations between brain-derived neurotrophic factor and clinical symptoms in medicated patients with major depression. J Affect Disord (2011) 135(1-3):332-5. doi:10.1016/j.jad.2011.06.041
136. Villanueva R. Neurobiology of major depressive disorder. Neural Plast (2013) 2013:873278. doi:10.1155/2013/873278
137. Karlovic D, Serretti A, Jevtovic S, Vrkic N, Seric V, Peleš AM. Diagnostic accuracy of serum brain derived neurotrophic factor concentration in antidepressant naïve patients with first major depression episode. J Psychiatr Res (2013) 47(2):162-7. doi:10.1016/j.jpsychires.2012.09.017
138. Jevtovic S, Karlovic D, Mihaljevic-Peleš A, Šeric V, Vrkic N, Jakšic N. Serum brain-derived neurotrophic factor (BDNF): the severity and symptomatic dimensions of depression. Psychiatr Danub (2011) 23(4):363-9.
139. Aydemir O, Deveci A, Taneli F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry (2005) 29(2):261-5. doi:10.1016/j.pnpbp.2004.11.009
140. Birkenhäger TK, Geldermans S, Van den Broek WW, van Beveren N, Fekkes D. Serum brain-derived neurotrophic factor level in relation to illness severity and episode duration in patients with major depression. J Psychiatr Res (2012) 46(3):285-9. doi:10.1016/j.jpsychires.2011.12.006
141. Dell'Osso L, Del Debbio A, Veltri A, Bianchi C, Roncaglia I, Carlini M, et al. Associations between brain-derived neurotrophic factor plasma levels and severity of the illness, recurrence and symptoms in depressed patients. Neuropsychobiology (2010) 62(4):207-12. doi:10.1159/000319946
142. Ninan PT, Shelton RC, Bao W, Guico-Pabia CJ. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine. Prog Neuropsychopharmacol Biol Psychiatry (2014) 48:86-91. doi:10.1016/j.pnpbp.2013.09.016
143. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry (2008) 64(6):527-32. doi:10.1016/j.biopsych.2008.05.005
144. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry (2003) 54(1):70-5. doi:10.1016/S0006-3223(03)00181-1
145. Yasui-Furukori N, Tsuchimine S, Nakagami T, Fujii A, Sato Y, Tomita T, et al. Association between plasma paroxetine concentration and changes in plasma brain-derived neurotrophic factor levels in patients with major depressive disorder. Hum Psychopharmacol (2011) 26(3):194-200. doi:10.1002/hup.1192
146. Lee HY, Kim YK. Plasma brain-derived neurotrophic factor as a peripheral marker for the action mechanism of antidepressants. Neuropsychobiology (2008) 57(4):194-9. doi:10.1159/000149817
147. Kurita M, Nishino S, Kato M, Numata Y, Sato T. Plasma brain-derived neurotrophic factor levels predict the clinical outcome of depression treatment in a naturalistic study. PLoS One (2012) 7(6):e39212. doi:10.1371/journal.pone.0039212
148. Molendijk ML, Bus BA, Spinhoven P, Penninx BW, Kenis G, Prickaerts J, et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry (2011) 16(11):1088-95. doi:10.1038/mp.2010.98
149. Hellweg R, Ziegenhorn A, Heuser I, Deuschle M. Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. Pharmacopsychiatry (2008) 41(2):66-71. doi:10.1055/s-2007-1004594
150. Munno D, Sterpone S, Fania S, Cappellin F, Mengozzi G, Saroldi M, et al. Plasma brain derived neurotrophic factor levels and neuropsychological aspects of depressed patients treated with paroxetine. Panminerva Med (2013) 55(4):377-84.
151. de Azevedo Cardoso T, Mondin TC, Wiener CD, Marques MB, Fucolo Bde Á, Pinheiro RT, et al. Neurotrophic factors, clinical features and gender differences in depression. Neurochem Res (2014) 39(8):1571-8. doi:10.1007/s11064-014-1349-4
152. Bus BA, Molendijk ML, Tendolkar I, Penninx BW, Prickaerts J, Elzinga BM, et al. Chronic depression is associated with a pronounced decrease in serum brain-derived neurotrophic factor over time. Mol Psychiatry (2015) 20(5):602-8. doi:10.1038/mp.2014.83
153. Anttila S, Huuhka K, Huuhka M, Rontu R, Hurme M, Leinonen E, et al. Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression. J Neural Transm (Vienna) (2007) 114(8):1065-8. doi:10.1007/s00702-007-0705-9
154. Gatt JM, Nemeroff CB, Dobson-Stone C, Paul RH, Bryant RA, Schofield PR, et al. Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol Psychiatry (2009) 14(7):681-95. doi:10.1038/mp.2008.143
155. Hwang JP, Tsai SJ, Hong CJ, Yang CH, Lirng JF, Yang YM. The Val66Met polymorphism of the brain-derived neurotrophic-factor gene is associated with geriatric depression. Neurobiol Aging (2006) 27(12):1834-7. doi:10.1016/j.neurobiolaging.2005.10.013
156. Licinio J, Dong C, Wong ML. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch Gen Psychiatry (2009) 66(5):488-97. doi:10.1001/archgenpsychiatry.2009.38
157. Ribeiro L, Busnello JV, Cantor RM, Whelan F, Whittaker P, Deloukas P, et al. The brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism and depression in Mexican-Americans. Neuroreport (2007) 18(12):1291-3. doi:10.1097/WNR.0b013e328273bcb0
158. Fuchikami M, Morinobu S, Segawa M, Okamoto Y, Yamawaki S, Ozaki N, et al. DNA methylation profiles of the brain-derived neurotrophic factor (BDNF) gene as a potent diagnostic biomarker in major depression. PLoS One (2011) 6(8):e23881. doi:10.1371/journal.pone.0023881
159. Kang HJ, Kim JM, Lee JY, Kim SY, Bae KY, Kim SW, et al. BDNF promoter methylation and suicidal behavior in depressive patients. J Affect Disord (2013) 151(2):679-85. doi:10.1016/j.jad.2013.08.001
160. Song Y, Miyaki K, Suzuki T, Sasaki Y, Tsutsumi A, Kawakami N, et al. Altered DNA methylation status of human brain derived neurotrophis factor gene could be useful as biomarker of depression. Am J Med Genet B Neuropsychiatr Genet (2014) 165B(4):357-64. doi:10.1002/ajmg.b.32238
161. Cirulli F, Alleva E. The NGF saga: from animal models of psychosocial stress to stress-related psychopathology. Front Neuroendocrinol (2009) 30(3):379-95. doi:10.1016/j.yfrne.2009.05.002
162. Diniz BS, Teixeira AL, Machado-Vieira R, Talib LL, Gattaz WF, Forlenza OV. Reduced serum nerve growth factor in patients with late-life depression. Am J Geriatr Psychiatry (2013) 21(5):493-6. doi:10.1016/j.jagp.2013.01.014
163. Martino M, Rocchi G, Escelsior A, Contini P, Colicchio S, de Berardis D, et al. NGF serum levels variations in major depressed patients receiving duloxetine. Psychoneuroendocrinology (2013) 38(9):1824-8. doi:10.1016/j.psyneuen.2013.02.009
164. Barbosa IG, Huguet RB, Neves FS, Reis HJ, Bauer ME, Janka Z, et al. Impaired nerve growth factor homeostasis in patients with bipolar disorder. World J Biol Psychiatry (2011) 12(3):228-32. doi:10.3109/15622975.2010.518629
165. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med (2008) 358(1):55-68. doi:10.1056/NEJMra073096
166. López-León S, Janssens AC, González-Zuloeta Ladd AM, Del-Favero J, Claes SJ, Oostra BA, et al. Meta-analyses of genetic studies on major depressive disorder. Mol Psychiatry (2008) 13(8):772-85. doi:10.1038/sj.mp.4002088
167. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry (2000) 157(10):1552-62. doi:10.1176/appi.ajp.157.10.1552
168. Gadow KD, Smith RM, Pinsonneault JK. Serotonin 2A receptor gene (HTR2A) regulatory variants: possible association with severity of depression symptoms in children with autism spectrum disorder. Cogn Behav Neurol (2014) 27(2):107-16. doi:10.1097/WNN.0000000000000028
169. Schulze TG, Müller DJ, Krauss H, Scherk H, Ohlraun S, Syagailo YV, et al. Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder. Am J Med Genet (2000) 96(6):801-3. doi:10.1002/1096-8628(20001204)96:6<801::AID-AJMG21>3.3.CO;2-W
170. Zhou Y, Wang J, He Y, Zhou J, Xi Q, Song X, et al. Association between dopamine beta-hydroxylase 19-bp insertion/deletion polymorphism and major depressive disorder. J Mol Neurosci (2015) 55(2):367-71. doi:10.1007/s12031-014-0339-y
171. Zhang ZJ, Wang D, Man SC, Ng R, McAlonan GM, Wong HK, et al. Platelet 5-HT(1A) receptor correlates with major depressive disorder in drug-free patients. Prog Neuropsychopharmacol Biol Psychiatry (2014) 53:74-9. doi:10.1016/j.pnpbp.2014.03.004
172. Ancelin ML, Carrière I, Scali J, Ritchie K, Chaudieu I, Ryan J. Angiotensin-converting enzyme gene variants are associated with both cortisol secretion and late-life depression. Transl Psychiatry (2013) 3:e322. doi:10.1038/tp.2013.95
173. Thiagarajah AS, Eades LE, Thomas PR, Guymer EK, Morand EF, Clarke DM, et al. GILZ: glitzing up our understanding of the glucocorticoid receptor in psychopathology. Brain Res (2014) 1574:60-9. doi:10.1016/j.brainres.2014.06.008
174. Frodl T, Carballedo A, Hughes MM, Saleh K, Fagan A, Skokauskas N, et al. Reduced expression of glucocorticoid-inducible genes GILZ and SGK-1: high IL-6 levels are associated with reduced hippocampal volumes in major depressive disorder. Transl Psychiatry (2012) 2:e88. doi:10.1038/tp.2012.14
175. Sprangers MA, Thong MS, Bartels M, Barsevick A, Ordoñana J, Shi Q, et al. Biological pathways, candidate genes, and molecular markers associated with quality-of-life domains: an update. Qual Life Res (2014) 23(7):1997-2013. doi:10.1007/s11136-014-0656-1
176. Cross-Disorder Group of the Psychiatric Genomics Consortium, Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 45(9):984-94. doi:10.1038/ng.2711
177. Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium, Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman MM, et al. A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry (2013) 18(4):497-511. doi:10.1038/mp.2012.21
178. Shi Y, Zhao X, Hsieh J, Wichterle H, Impey S, Banerjee S, et al. MicroRNA regulation of neural stem cells and neurogenesis. J Neurosci (2010) 30(45):14931-6. doi:10.1523/JNEUROSCI.4280-10.2010
179. Im HI, Kenny PJ. MicroRNAs in neuronal function and dysfunction. Trends Neurosci (2012) 35(5):325-34. doi:10.1016/j.tins.2012.01.004
180. Belzeaux R, Bergon A, Jeanjean V, Loriod B, Formisano-Tréziny C, Verrier L, et al. Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl Psychiatry (2012) 2:e185. doi:10.1038/tp.2012.112
181. Bocchio-Chiavetto L, Maffioletti E, Bettinsoli P, Giovannini C, Bignotti S, Tardito D, et al. Blood microRNA changes in depressed patients during antidepressant treatment. Eur Neuropsychopharmacol (2013) 23(7):602-11. doi:10.1016/j.euroneuro.2012.06.013
182. He Y, Zhou Y, Xi Q, Cui H, Luo T, Song H, et al. Genetic variations in microRNA processing genes are associated with susceptibility in depression. DNA Cell Biol (2012) 31(9):1499-506. doi:10.1089/dna.2012.1660
183. Saus E, Soria V, Escaramís G, Vivarelli F, Crespo JM, Kagerbauer B, et al. Genetic variants and abnormal processing of pre-miR-182, a circadian clock modulator, in major depression patients with late insomnia. Hum Mol Genet (2010) 19(20):4017-25. doi:10.1093/hmg/ddq316
184. Liu X, Zhang L, Cheng K, Wang X, Ren G, Xie P. Identification of suitable plasma-based reference genes for miRNAome analysis of major depressive disorder. J Affect Disord (2014) 163:133-9. doi:10.1016/j.jad.2013.12.035
185. Szebeni A, Szebeni K, DiPeri T, Chandley MJ, Crawford JD, Stockmeier CA, et al. Shortened telomere length in white matter oligodendrocytes in major depression: potential role of oxidative stress. Int J Neuropsychopharmacol (2014) 17(10):1579-89. doi:10.1017/S1461145714000698
186. Teyssier JR, Chauvet-Gelinier JC, Ragot S, Bonin B. Up-regulation of leucocytes genes implicated in telomere dysfunction and cellular senescence correlates with depression and anxiety severity scores. PLoS One (2012) 7(11):e49677. doi:10.1371/journal.pone.0049677
187. Hoen PW, Rosmalen JG, Schoevers RA, Huzen J, van der Harst P, de Jonge P. Association between anxiety but not depressive disorders and leukocyte telomere length after 2 years of follow-up in a population-based sample. Psychol Med (2013) 43(4):689-97. doi:10.1017/S0033291712001766
188. Wolkowitz OM, Mellon SH, Epel ES, Lin J, Dhabhar FS, Su Y, et al. Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress-preliminary findings. PLoS One (2011) 6(3):e17837. doi:10.1371/journal.pone.0017837
189. Mitchell C, Hobcraft J, McLanahan SS, Siegel SR, Berg A, Brooks-Gunn J, et al. Social disadvantage, genetic sensitivity, and children's telomere length. Proc Natl Acad Sci U S A (2014) 111(16):5944-9. doi:10.1073/pnas.1404293111
190. Gotlib IH, LeMoult J, Colich NL, Foland-Ross LC, Hallmayer J, Joormann J, et al. Telomere length and cortisol reactivity in children of depressed mothers. Mol Psychiatry (2015) 20(5):615-20. doi:10.1038/mp.2014.119
191. Cai N, Chang S, Li Y, Li Q, Hu J, Liang J, et al. Molecular signatures of major depression. Curr Biol (2015) 25(9):1146-56. doi:10.1016/j.cub.2015.03.008
192. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry (2003) 160(4):636-45. doi:10.1176/appi.ajp.160.4.636
193. Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for major depression. Neuropsychopharmacology (2004) 29(10):1765-81. doi:10.1038/sj.npp.1300506
194. Goldstein BL, Klein DN. A review of selected candidate endophenotypes for depression. Clin Psychol Rev (2014) 34(5):417-27. doi:10.1016/j.cpr.2014.06.003
195. Nestler EJ, Peña CJ, Kundakovic M, Mitchell A, Akbarian S. Epigenetic basis of mental illness. Neuroscientist (2015). doi:10.1177/1073858415608147
196. Covington HE III, Maze I, LaPlant QC, Vialou VF, Ohnishi YN, Berton O, et al. Antidepressant actions of histone deacetylase inhibitors. J Neurosci (2009) 29(37):11451-60. doi:10.1523/JNEUROSCI.1758-09.2009
197. Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci (2007) 8(5):355-67. doi:10.1038/nrn2132
198. Covington HE III, Vialou VF, LaPlant Q, Ohnishi YN, Nestler EJ. Hippocampal-dependent antidepressant-like activity of histone deacetylase inhibition. Neurosci Lett (2011) 493(3):122-6. doi:10.1016/j.neulet.2011.02.022
199. Covington HE III, Maze I, Vialou V, Nestler EJ. Antidepressant action of HDAC inhibition in the prefrontal cortex. Neuroscience (2015) 298:329-35. doi:10.1016/j.neuroscience.2015.04.030
200. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci (2006) 9(4):519-25. doi:10.1038/nn1659
201. Maussion G, Yang J, Suderman M, Diallo A, Nagy C, Arnovitz M, et al. Functional DNA methylation in a transcript specific 3'UTR region of TrkB associates with suicide. Epigenetics (2014) 9(8):1061-70. doi:10.4161/epi.29068
202. Januar V, Saffery R, Ryan J. Epigenetics and depressive disorders: a review of current progress and future directions. Int J Epidemiol (2015) 44(4):1364-87. doi:10.1093/ije/dyu273
203. Numata S, Ishii K, Tajima A, Iga J, Kinoshita M, Watanabe S, et al. Blood diagnostic biomarkers for major depressive disorder using multiplex DNA methylation profiles: discovery and validation. Epigenetics (2015) 10(2):135-41. doi:10.1080/15592294.2014.1003743
204. Kinoshita M, Numata S, Tajima A, Shimodera S, Ono S, Imamura A, et al. DNA methylation signatures of peripheral leukocytes in schizophrenia. Neuromolecular Med (2013) 15(1):95-101. doi:10.1007/s12017-012-8198-6
205. Smart C, Strathdee G, Watson S, Murgatroyd C, McAllister-Williams RH. Early life trauma, depression and the glucocorticoid receptor gene-an epigenetic perspective. Psychol Med (2015) 45(16):3393-410. doi:10.1017/S0033291715001555
206. Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR, et al. Epigenetic programming by maternal behavior. Nat Neurosci (2004) 7(8):847-54. doi:10.1038/nn1276
207. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature (2003) 422(6928):198-207. doi:10.1038/nature01511
208. Martins-de-Souza D, Maccarrone G, Wobrock T, Zerr I, Gormanns P, Reckow S, et al. Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J Psychiatr Res (2010) 44(16):1176-89. doi:10.1016/j.jpsychires.2010.04.014
209. Miller CL, Llenos IC, Cwik M, Walkup J, Weis S. Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. Neurochem Int (2008) 52(6):1297-303. doi:10.1016/j.neuint.2008.01.013
210. Martins-de-Souza D, Guest PC, Harris LW, Vanattou-Saifoudine N, Webster MJ, Rahmoune H, et al. Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. Transl Psychiatry (2012) 13(2):e87. doi:10.1038/tp.2012.13
211. Lindon JC, Holmes E, Nicholson JK. So what's the deal with metabonomics? Anal Chem (2003) 75(17):384A-91A. doi:10.1021/ac031386+
212. Ding X, Yang S, Li W, Liu Y, Li Z, Zhang Y, et al. The potential biomarker panels for identification of major depressive disorder (MDD) patients with and without early life stress (ELS) by metabonomic analysis. PLoS One (2014) 9(5):e97479. doi:10.1371/journal.pone.0097479
213. Heim C, Nemeroff CB. The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biol Psychiatry (2001) 49(12):1023-39. doi:10.1016/S0006-3223(01)01157-X
214. Zheng P, Chen JJ, Huang T, Wang MJ, Wang Y, Dong MX, et al. A novel urinary metabolite signature for diagnosing major depressive disorder. J Proteome Res (2013) 12(12):5904-11. doi:10.1021/pr400939q
215. Lu YR, Fu XY, Shi LG, Jiang Y, Wu JL, Weng XJ, et al. Decreased plasma neuroactive amino acids and increased nitric oxide levels in melancholic major depressive disorder. BMC Psychiatry (2014) 14:123. doi:10.1186/1471-244X-14-123
216. Ditzen C, Tang N, Jastorff AM, Teplytska L, Yassouridis A, Maccarrone G, et al. Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology. Neuropsychopharmacology (2012) 37(4):1013-25. doi:10.1038/npp.2011.285
217. Wang Y, Chen J, Chen L, Zheng P, Xu HB, Lu J, et al. Urinary peptidomics identifies potential biomarkers for major depressive disorder. Psychiatry Res (2014) 217(1-2):25-33. doi:10.1016/j.psychres.2014.02.029
218. Papakostas GI, Shelton RC, Kinrys G, Henry ME, Bakow BR, Lipkin SH, et al. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. Mol Psychiatry (2013) 18(3):332-9. doi:10.1038/mp.2011.166
219. Bilello JA, Thurmond LM, Smith KM, Pi B, Rubin R, Wright SM, et al. MDDScore: confirmation of a blood test to aid in the diagnosis of major depressive disorder. J Clin Psychiatry (2015) 76(2):e199-206. doi:10.4088/JCP.14m09029
220. Lindqvist D, Janelidze S, Erhardt S, Träskman-Bendz L, Engström G, Brundin L. CSF biomarkers in suicide attempters-a principal component analysis. Acta Psychiatr Scand (2011) 124(1):52-61. doi:10.1111/j.1600-0447.2010.01655.x
221. Maccarrone G, Ditzen C, Yassouridis A, Rewerts C, Uhr M, Uhlen M, et al. Psychiatric patient stratification using biosignatures based on cerebrospinal fluid protein expression clusters. J Psychiatr Res (2013) 47(11):1572-80. doi:10.1016/j.jpsychires.2013.07.021
222. Cuthbert BN. Research domain criteria: toward future psychiatric nosologies. Dialogues Clin Neurosci (2013) 17(1):89-97.
223. Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med (2013) 11:126. doi:10.1186/1741-7015-11-126
224. Owen MJ. New approaches to psychiatric diagnostic classification. Neuron (2014) 84(3):564-71. doi:10.1016/j.neuron.2014.10.028
225. Lakhan SE, Vieira K, Hamlat E. Biomarkers in psychiatry: drawbacks and potential for misuse. Int Arch Med (2010) 3:1. doi:10.1186/1755-7682-3-1